Myrobalan Therapeutics

Myrobalan Therapeutics and other biotech companies have recently been made aware of a growing number of email scams targeting job candidates in our industry. Our recruiters at Myro use @myrotx.com email addresses exclusively. We do not ask candidates to purchase anything through us or to provide sensitive identifiable information via email. You will also never get a text from our recruitment team regarding a job application. If a person claiming to be a Myro recruiter with an alternative domain reaches out to you regarding a job posting, please report it to our team by emailing info@myrotx.com with details. 

This Sunday, the Myrobalan Therapeutics team was honored to participate in the ALS Association's Walk to Defeat ALS in Boston. Walking alongside patients, families, and advocates was a humbling reminder of why we are committed to advancing innovative therapies for neuroinflammatory diseases like ALS. Together, we can make strides toward a future without ALS! 💙 #WalkToDefeatALS #ALSResearch #Neuroinflammation #TeamMyrobalan #BostonEvents #ALS

We'd like to extend a warm welcome to Ms. Emma Reeve, our newest Board Member! With over 30 years of financial leadership in biotech, Emma brings invaluable expertise to Myrobalan as the company plans to grow and advance its programs into the clinic. Previously, Emma served as Chief Financial Officer at Constellation Pharmaceuticals through the successful IPO in 2018 and its ultimate acquisition by MorphoSys AG in 2021. Before her time at Constellation, Ms. Reeve was the interim Chief Financial Officer and Corporate Controller at Parexel. Emma Reeve currently serves as Chair of the Board at Editas Medicine and is a board member at PTC Therapeutics, Aadi Bioscience, Cardurion Pharma, and ReAlta Life Sciences. We look forward to paving the path forward together with Emma! https://lnkd.in/ecZrUaxn https://lnkd.in/e-ywMGjm

Myrobalan is proud to be a local sponsor of the Walk to Defeat ALS in Boston on Oct 20th. This signature event is focused on supporting and advocating for patients and families living with ALS, a prominent and debilitating neurodegenerative disease with no cure. Myrobalan is deeply committed to discovering first and best-in-class small molecule treatments for neurodegenerative diseases such as ALS. Help us make strides toward treatments and cures by donating to the ALS Association. 

We are excited to present our poster on our oral, CNS-penetrant CSF1R inhibitor at the Society for Neuroscience 2024 in Chicago! We look forward to making strides toward therapies for patients suffering from neuroinflammatory diseases.   🧠 Title: Targeting Chronically Active Microglia: CSF1R Inhibition for Treating Multiple Sclerosis 🗓 Date: Sunday, October 6, 2024 ⏰ Time: 1:00- 5:00 p.m. Central Time 📍 Session: Multiple Sclerosis, Leukodystrophies, and Oligodendrocyte Myelination Poster#: PSTR105.18   #SfN24 #Neuroscience #Innovation #Neuroinflammation

We are thrilled to announce the creation of a new role at Myrobalan: Interim Chief Medical Officer (CMO). This position reflects our growing commitment to advancing our pipeline and bringing life-changing therapies to patients in need. With our lead program moving into the clinic next year, having strong medical and clinical leadership is more crucial than ever. We’re looking forward to welcoming a passionate and experienced leader who will help guide us through this pivotal phase and beyond. Stay tuned for more updates as we continue to expand our team and capabilities! #Hiring

ICYMI, we are presenting data on our GPR17 program at ECTRIMS today! https://lnkd.in/ev4djYms

We are pleased to announce our upcoming poster presentation at ECTRIMS 2024 in Copenhagen! Our team will be showcasing a poster on our GPR17 antagonist program, a novel remyelination target. 🗓 Date: Wednesday, 18 September 2024 ⏰ Time: 16:15 – 18:15 CEST 📍 Location: Poster Session 1, Poster # P171 Join us to learn more about our research aimed at developing innovative therapies for demyelinating diseases. #ECTRIMS2024 #Remyelination #DemyelinatingDiseases #Neuroscience #GPR17 #Innovation

We are thrilled to welcome Grant Bogle to the Board of Directors at Myrobalan Therapeutics!   Grant brings a wealth of experience, having served as CEO of Epizyme, Inc. from 2021-2022 and as a Board Member from 2019-2022 until its acquisition by Ipsen in 2022. Prior to that, he was the SVP and COO of TESARO, which was acquired by GSK for $5.1B in 2018. He has also held senior executive roles at several other renowned pharmaceutical and biotech companies, including Millennium, ViaCord, Roche, Knoll, and McKesson Specialty Health/U.S. Oncology.   This announcement comes just a month after Myrobalan Therapeutics raised an additional $9 million from three new investors in a subsequent closing of its Series A round, bringing total Series A funding to $33 million.   We are incredibly excited to have Grant join us as we continue our journey as a leading CNS biotech company. Welcome to the Board, Grant! See the full press release here: https://lnkd.in/e-P56Gqd https://lnkd.in/epiw4ESZ

Yesterday, the Myrobalan Therapeutics Medford team traded our laptops for life vests, paddles, and kayaks. We had an amazing time heading down the Mystic River, where we saw turtles, herons, and other local wildlife. We hope they weren't too disturbed by our kayak dodgeball game…😆   Here’s to many more adventures together and to the wonderful team that makes Myrobalan a great place to work!